Differentiation into multiple mesodermal lineages

The term "Differentiation into multiple mesodermal lineages" refers to the biological process by which pluripotent stem cells or early progenitor cells undergo specification and commitment, through regulated signaling pathways (e.g., BMP, Activin, WNT), to generate a variety of mature cell types derived from the mesoderm germ layer. These cell types include hematopoietic (blood), endothelial (vessel), mesenchymal (bone, cartilage, fat, fibroblasts), muscle (cardiac, skeletal, smooth), and other lineages[1][2][3][4]. This process is controlled by networks of transcription factors, cell surface markers, and extrinsic signals, but it does not represent a discrete molecule or receptor[1][3][4]. The numerous cited studies focus on the characterization and manipulation of the differentiation process from pluripotency to mesodermal lineages and do not identify a single molecular entity with a canonical name or abbreviation that is a direct therapeutic target; rather, they describe various intermediate progenitor populations, changes in marker expression (e.g., CD326−CD56+ cells), and usage of growth factors such as BMP4 and Activin for experimental manipulation[2][3][4][6]. These are experimental tools and conceptual stages, not molecular "targets" as defined in drug discovery. "Differentiation into multiple mesodermal lineages" should not be mapped to a molecule or receptor target entry. If detailed information on key regulatory genes, proteins, or pathways involved in mesoderm differentiation (e.g., Brachyury, BMP4 receptor, Activin receptor) is needed, it would be appropriate to specify them individually to generate a valid entry[2][3][4].